|Bid||163.08 x 900|
|Ask||163.31 x 800|
|Day's range||159.91 - 169.26|
|52-week range||121.32 - 464.00|
|Beta (5Y monthly)||-0.70|
|PE ratio (TTM)||5.17|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||2.11 (1.33%)|
|Ex-dividend date||02 Jun 2022|
|1y target est||320.42|
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.
Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).
Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.